LeMaitre Vascular

LeMaitre Vascular, Inc. engages in the provision of medical devices and human tissue cryopreservation services. The company focuses on the design, marketing, sales, service, and technical support of medical devices and implants for the treatment of peripheral vascular disease. Its products include balloon catheters, carotid shunts, biologic patches, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, vascular grafts, and powered phlebectomy. The company was founded by George D. LeMaitre on November 28, 1983 and is headquartered in Burlington, MA.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LeMaitre (LMAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: LeMaitre Vascular (LMAT) Q1 Earnings Expected to Decline

Genuine Parts

Catching The Bottom

BURLINGTON, Mass., April  13, 2020  (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT), a provider of vascular devices, implants and services, announced today Q1 2020 preliminary, unaudited results and withdrew prior annual guidance for 2020 due to the potential impact of COVID-19.

LeMaitre Vascular Withdraws Prior Annual Guidance for 2020 And Announces Preliminary Q1 2020 Financial Results

Fulgent Genetics

Semler Scientific

We take a look at three small and promising healthcare companies across diagnostics, surgical products, and genetic testing.

3 Exciting Healthcare Stocks

LeMaitre Vascular, Inc. (LMAT) CEO George LeMaitre on Q4 2019 Results - Earnings Call Transcript

LeMaitre (LMAT) delivered earnings and revenue surprises of 0.00% and -1.05%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

LeMaitre Vascular (LMAT) Q4 Earnings Match Estimates

Duke Realty

Sabre

3 Stocks With Fast-Growing Earnings: DRE, LMAT & SABR

Descartes Systems Group

General Dynamics

General Electric

Mastercard

MSC Industrial Direct

Omnicom Group

Pitney Bowes

Alkaline Water Company Inc (The)

Looking for a shopping list of stocks to add to your portfolio? Each year, MoneyShow asks the nation’s leading financial newsletter advisors for their top stock ideas for the year.

10 Top Picks Financial Newsletter Advisors Love For 2020

Align Technology

Edwards Lifesciences

Globus Medical

QuidelOrtho Corp

Repligen

ResMed

Medical technology companies are rising bullishly in 2019. The best-performing medical stocks tend to have high Composite Ratings, reflecting strong growth metrics vs.

These Medical Stocks Are Outperforming 95% Of All Stocks — Here's Why

National Vision Hlds

EYE vs. LMAT: Which Stock Is the Better Value Option?

LeMaitre Vascular, Inc. (LMAT) CEO George LeMaitre on Q3 2019 Results - Earnings Call Transcript

LeMaitre (LMAT) delivered earnings and revenue surprises of 19.05% and 3.56%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

LeMaitre Vascular (LMAT) Q3 Earnings and Revenues Beat Estimates

LeMaitre Vascular (LMAT) Reports Next Week: What to Know Ahead of the Release

BURLINGTON, Mass., Oct.  13, 2019  (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), announced that it has acquired the biologic patch business of Admedus Ltd (ASX: AHZ) for $15.5 million, of which $14.2 million was paid at closing and $1.3 million is due in two post-closing installments, as well as potential earnout payments of $7.8 million payable based upon performance of the acquired business as well as other milestones.  The parties also signed a license agreement for the tissue processing technology limited to the CardioCel and VascuCel product lines and a transition services agreement under which Admedus will continue to manufacture the products for up to three years while LeMaitre Vascular transitions manufacturing to its US headquarters.  LeMaitre Vascular will not take ownership of the Admedus factory in Perth, Australia.

LeMaitre Vascular Acquires Biologic Patch Business from Admedus

EYE vs. LMAT: Which Stock Should Value Investors Buy Now?

Chairman and CEO of Lemaitre Vascular Inc (30-Year Financial, Insider Trades) George W Lemaitre (insider trades) sold 66,037 shares of LMAT on 07/25/2019 at an average price of $34.45 a share.

Lemaitre Vascular Inc (LMAT) Chairman and CEO George W Lemaitre Sold $2.3 million of Shares

LeMaitre Vascular Inc. (LMAT) CEO George LeMaitre on Q2 2019 Results - Earnings Call Transcript

LeMaitre (LMAT) delivered earnings and revenue surprises of 9.52% and 1.89%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

LeMaitre Vascular (LMAT) Surpasses Q2 Earnings and Revenue Estimates

LeMaitre Vascular, Inc. (LMAT) CEO George LeMaitre on Q1 2019 Results - Earnings Call Transcript

LeMaitre Vascular (LMAT) Q1 Earnings Preview: What's in the Cards?

News for LeMaitre Vascular Stock (LMAT)